David Downs is a Senior Editor at various prominent publications. He specializes in cannabis and psychedelics, focusing on cannabis business and regulation, which are central themes in his work. David has been featured in notable outlets such as Newsroom NZ, Billboard, Leafly, and High Times, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
David's articles primarily focus on the cannabis industry within the United States, particularly highlighting specific strains and related topics. His coverage includes seasonal content, government announcements, promotional deals, and legal policy regulation.
Given his emphasis on health and product promotions in the cannabis sector, David may be interested in pitches that offer insights into emerging trends or new developments related to cannabis strains or products. As he frequently covers specific companies such as Seed Junky Genetics and platforms like Leafly, he might respond well to pitches about innovative products or advancements from these entities.
Considering his interest in local US-focused content regarding cannabis legalization and strain analysis, experts with knowledge of regional variations in regulations or unique insights into popular strains could capture David's attention for potential contributions.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The move to Schedule III acknowledges medical use, but leaves federal control, consolidation fears, and unfinished justice intact.
Fun fact: the federal government will not approve one dollar of funding for any cannabis research looking into the benefits of the plant. Bias is baked into the rules for the federal bureaucracy at the National Institute on Drug Abuse, which gets the sign-off on such research dollars. Cannabis research has to run a gauntlet that no other drug does, with both its arms tied behind its back. And yet more of its benefits leaked out again this year. Here are 10 of the top cannabis health studies from 2025 that defied the decades-old institutional bias.
From hemp recriminalization to Germany's cannabis boom, explore 2025's biggest cannabis moments — including New York's $1B milestone, Zangbanger's rise, and the shift away from alcohol.
The year ahead: The coming year may seem hard to navigate but getting lost is one of life's joys; finding your way through is one of life's lessons. So argues the man tasked with telling New Zealand's story.
A just-for-fun poll yielded a solid lineup of greatness including Bodhi, CSI Humboldt, Capulator, and Archive Seed Bank.
Matthew Indest, Ph.D., taps his experience in conventional agriculture and horticulture breeding programs and extensive work in cannabis and hemp to share insights into breeding technologies set to change cannabis the fastest, important automation impacts, the science of drying and curing, and more.
By: David Downs
Brian Vicente of Vicente LLP talks Schedule III with Cannabis Business Times
A new California bill would ban video games on vapes, resulting in a fine of up to $50,000 for manufacturers.
Moon Valley Cannabis founder Eli Buffalo dives into living soil and Korean Natural Farming, challenges with scaling and more in this candid interview.
Aficionado Seeds' decades-long crusade to spread the “real” Sour Diesel. “Is that the real Sour Diesel?…I remember it differently…It's gone extinct…”
